Drug Profile


Alternative Names: IdB 1016

Latest Information Update: 18 Apr 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Inverni della Beffa
  • Developer Indena; Inverni della Beffa
  • Class Antivirals; Hepatoprotectants
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Hepatitis C; Liver disorders; Ovarian cancer

Most Recent Events

  • 07 Oct 2004 Phase-II clinical trials in Ovarian cancer in Italy (PO)
  • 06 Sep 1999 No-Development-Reported for Hepatitis C in Italy (PO)
  • 30 Aug 1999 Sanofi and Synthélabo have merged to form Sanofi-Synthélabo
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top